{"editorial":{"content_id":"ecc9e234-3fc3-4a05-a7f2-3710a54f1d93","slug":"anvisa-keytruda-20261019-37d660","content_type":"news","title":"巴西Anvisa查扣Keytruda两个伪造批次","summary":"巴西国家卫生监督局下令查扣Keytruda（帕博利珠单抗）100 mg/4 mL的两个疑似伪造批次。","body":"巴西国家卫生监督局（Anvisa）10月19日（周一）下令查扣Keytruda（帕博利珠单抗）100 mg/4 mL的伪造批次，该药用于治疗多种癌症。\n\n持有该产品注册的Merck Sharp & Dohme Farmacêutica Ltda.在市场上发现批号为Z005197和Z012354的药品单位，其特征与正品不符，怀疑为伪造产品。\n\nAnvisa就此发布了第4.105/2026号决议，刊登于联邦官方公报（DOU）。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["合规","法律","行业趋势","br-health"],"content_level":"编辑整理","event_type":"政策法规","audience_tags":[],"event_location":null,"verification_status":"source_verified","published_at":"2026-10-19T17:01:40.347Z","display_date":"2026-10-19","source_published_at":null,"source_url":"https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-lotes-falsificados-do-medicamento-keytruda","source_name":"Anvisa","source_language":"pt","author_name":"编辑部","risk_level":"low","risk_flags":["compliance_risk","legal_risk"],"opportunity_flags":[],"trend_signals":["regulatory_enforcement_strengthening"]},"intelligence":{"intel_id":"44f552ef-ecf8-40ca-ae8c-3849d15ae49f","version":1,"event_type":"风险事件","event_date":"2026-10-19","main_entities":[{"name":"巴西国家卫生监督局（Anvisa）","role":"下令查扣疑似伪造药品批次并发布决议","type":"regulator","country":"巴西","normalized_name":null},{"name":"Keytruda（帕博利珠单抗）","role":"被查扣两个疑似伪造批次的肿瘤治疗药品","type":"product","country":"巴西","normalized_name":null},{"name":"Merck Sharp & Dohme Farmacêutica Ltda.","role":"Keytruda在巴西的注册持有人，发现特征与正品不符的药品单位","type":"company","country":"巴西","normalized_name":null}],"main_action":"Anvisa下令查扣Keytruda两个疑似伪造批次并发布决议","key_numbers":[{"unit":"mg/4 mL","label":"规格","value":"100"},{"unit":"批号","label":"疑似伪造批号","value":"Z005197、Z012354"},{"unit":"号","label":"决议编号","value":"4.105/2026"}],"facts":[{"verified":false,"statement":"Anvisa于10月19日下令查扣Keytruda（帕博利珠单抗）100 mg/4 mL的两个疑似伪造批次。","source_excerpt":null},{"verified":false,"statement":"Merck Sharp & Dohme Farmacêutica Ltda.在市场上发现批号为Z005197和Z012354的药品单位，其特征与正品不符并怀疑为伪造产品。","source_excerpt":null},{"verified":false,"statement":"Anvisa就此发布了第4.105/2026号决议，并刊登于联邦官方公报（DOU）。","source_excerpt":null}],"assessments":[{"statement":"伪造肿瘤治疗药品流入市场可能对患者安全和药品供应链完整性构成较高风险。","confidence":"medium","basis_fact_index":null},{"statement":"该查扣行动表明巴西监管机构正在加强对高风险药品流通环节的执法。","confidence":"medium","basis_fact_index":null}],"actions":[{"target":"both","priority":"high","description":"核验供应链中是否出现批号Z005197和Z012354的Keytruda产品，并暂停相关批次流通。"},{"target":"both","priority":"high","description":"跟进Anvisa第4.105/2026号决议及DOU公告，确认查扣范围和后续召回要求。"},{"target":"user","priority":"normal","description":"向药品采购、药房和药物警戒团队发布伪造批次风险提示。"}],"affected_audience":["癌症患者","医疗机构和医生","药品经销商和进口商","药房","药物警戒团队"],"risk_flags":["compliance_risk","legal_risk"],"opportunity_flags":[],"trend_signals":["regulatory_enforcement_strengthening"],"follow_up_needed":true,"follow_up_questions":["Anvisa第4.105/2026号决议的完整内容和官方链接是什么？","两个疑似伪造批次是否已确认流通范围、数量和具体流向？","是否已有患者使用相关批次及不良事件报告？"],"related_topics":["Keytruda","帕博利珠单抗","Anvisa","伪造药品","药品监管","巴西"],"verification_status":"unverified","confidence_score":0.7,"generated_at":"2026-10-19T17:01:53.101Z"},"meta":{"canonical_url":"https://chinabrazilinsight.com/news/anvisa-keytruda-20261019-37d660","api_url":"https://chinabrazilinsight.com/api/public/content/anvisa-keytruda-20261019-37d660","markdown_url":"https://chinabrazilinsight.com/api/public/content/anvisa-keytruda-20261019-37d660?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/anvisa-keytruda-20261019-37d660?view=json","last_updated":"2026-10-19T17:01:54.334Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}